Mutabilis, Romainville, France
NON-BETA-LACTAM PBP INHIBITOR (DABOCINS)
New class antibacterial to treat CRE infections
Mutabilis is developing new intravenous drug, EBL-1463, a novel class of non-beta-lactam inhibitor of penicillin binding proteins (PBPs) called dabocins, to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. The new drug kills bacteria in the same efficient way as beta-lactams – by interfering with the cell wall synthesis of the bacteria. Contrary to beta-lactams, however, EBL-1463 shows unmatched stability to class A, B, C and D beta-lactamases. Further, it is unaffected by PBP3-based resistance mutations identified in E. coli. The project is in the preclinical phase. With CARB-X support, Mutabilis aims to progress EBL-1463 through IND-enabling studies.
Current Development Stage: Preclinical
CARB-X Investment: Initial investment of up to $6.4m, with potential option payments up to $5.8m.
Initial CARB-X Investment Date: September 1, 2020